← Back to Search

Behavioral Intervention

Communication Tool Adaptation for HIV Prevention (PrEP Trial)

N/A

Waitlist Available

Led By Mirjam-Colette Kempf, PhD, MPH

Research Sponsored by University of Alabama at Birmingham

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Cisgender African American HIV-uninfected women aged 18 years or older who speak English and report HIV risk and/or recent PrEP use

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3 months and 12 months

Awards & highlights

No Placebo-Only Group

Summary

This trial will adapt and test a communication tool to increase PrEP uptake among at-risk African American women in rural areas of the southern US.

Who is the study for?

This trial is for African American, cisgender women over the age of 18 who speak English and are at risk for HIV but not infected. They should recognize their HIV risk or have used PrEP recently. Healthcare providers such as physicians, nurses, or social workers cannot participate.

What is being tested?

The study aims to increase PrEP uptake among at-risk African American women in rural Alabama by adapting a communication tool from the CDC's PrEP toolkit. This tool will help with recognizing HIV risk and interest in starting PrEP through referrals to local clinics.

What are the potential side effects?

Since this trial focuses on cultural adaptation of a communication tool rather than a medical intervention, traditional side effects associated with medications are not applicable here.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am an African American woman over 18, speak English, at risk for HIV or have used PrEP recently.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3 months and 12 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3 months and 12 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months and 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Intervention acceptability

Intervention feasibility changes

PrEP uptake changes

Secondary study objectives

Clinic visit adherence changes

PrEP adherence

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Cultural adaptation of a patient-provider communication toolExperimental Treatment1 Intervention

Strengthening of the PrEP care continuum by developing and testing an intervention designed to improve PrEP awareness, screening, engagement, retention, adherence, and persistence among individuals at substantial risk for HIV infection; developing and testing an intervention to reduce racial/disparities in PrEP uptake and use.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Cultural adaptation of a patient-provider communication tool

2020

N/A

~70

0 / 1Eligibility criteria met